Purpose Uncertainty exists regarding comparative effectiveness of cetuximab versus
bevacizumab in metastatic colorectal cancer (mCRC). We conducted a retrospective head-to …

Background Cetuximab and bevacizumab reportedly improve the survival of patients with
metastatic colorectal cancer (mCRC), but their most effective sequence of administration is …

BACKGROUND: Chemotherapy combinations and addition of cetuximab or bevacizumab to
chemotherapy have been shown to improve overall survival of metastatic colorectal cancer …

Background: Colorectal cancer is one of the most common malignancies in the United
States, with a large proportion of patients presenting with metastatic disease or developing a …

The present observational cohort study was designed to elucidate the efficacy and safety
profile of bevacizumab or cetuximab with chemotherapy as the first-line treatment in Chinese …

Purpose We aimed to compare the treatment efficacy of cetuximab versus bevacizumab in
combination with either irinotecan-based or oxaliplatin-based regimens (targeted triplet) as …

Evidence available on the effectiveness and costs of biological therapies for the initial
treatment of metastatic colorectal cancer (mCRC) is scarce and contrasting. We conducted a …

Background Combination irinotecan and cetuximab is approved for irinotecan-refractory
metastatic colorectal cancer (mCRC). It is unknown if adding bevacizumab improves …

Simple Summary The current metastatic colorectal cancer guidelines suggest intensive
systemic chemotherapy with a targeted agent, rather than surgical resection, as first-line …

Objective: To estimate the efficacy and safety of adding bevacizumab to cetuximab-or
panitumumab-based therapy in the treatment of patients with metastatic colorectal cancer …